## Chemically Enhanced Peptide and Protein Therapeutics

## Guest Editors:

## Dr. Benjamí Oller-Salvia

GEMAT, Department of Bioengineering, Institut Químic de Sarrià, Universitat Ramon Llull, 08017 Barcelona, Spain

## Dr. Noriyasu Kamei

Laboratory of Drug Delivery Systems, Faculty of
Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan

Deadline for manuscript submissions:
closed (30 December 2022)

## Message from the Guest Editors

The approval of peptide and protein therapeutics by medicinal regulatory agencies is on the rise. Biotherapeutics have exquisite selectivity and have proven capable of engaging targets considered undruggable with small molecules. However, natural peptides and proteins may present limited circulation half-lives or limited cellkilling efficiency. Chemistry provides many opportunities to address these and other challenges, thereby increasing the efficacy of biotherapeutics. Some examples of "chemical enhancement" include peptide cyclization to increase protease stability, the insertion of noncanonical amino acids with functional groups that increase target affinity, anchoring polymer chains to reduce glomerular filtration, and the conjugation of cytotoxic molecules to enhance therapeutic efficacy. In this Special Issue, we welcome research articles reporting recent advances in this rapidly growing field, including chemically modified peptides and proteins as stand-alone therapeutics or targeting moieties.

- noncanonical amino acids
- peptide therapeutics
- targeting peptides
- peptidomimetics
- protein therapeutics
- antibody-drug conjugates


## Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of
Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

## Contact Us

Pharmaceutics Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland

Tel: +41 616837734
www.mdpi.com
mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma

